acut
respiratori
distress
syndrom
ard
induc
viral
diseas
two
viru
type
respons
respiratori
virus
caus
communityacquir
viral
pneumonia
herpesvirida
caus
nosocomi
viral
pneumonia
among
respiratori
virus
affect
lung
caus
ard
pandem
virus
head
list
influenza
virus
recent
identifi
howev
virus
caus
sever
ard
notabl
novel
coronaviru
respons
sever
acut
respiratori
syndrom
outbreak
apart
pandem
virus
respiratori
virus
rare
respons
viral
pneumonia
ard
antivir
drug
mainli
oseltamivir
administr
avoid
corticosteroid
manag
ard
due
virus
differ
ard
caus
diseas
among
herpesvirida
herp
simplex
viru
hsv
cytomegaloviru
cmv
two
virus
caus
nosocomi
viral
pneumonia
evolv
ard
hsv
frequent
recov
respiratori
tract
mechan
ventil
patient
sometim
respons
hsv
bronchopneumon
although
evalu
indic
acyclovir
therapeut
option
patient
hsv
bronchopneumon
ard
cmv
pneumonia
also
occur
mechan
ventil
patient
difficult
diagnos
viru
recoveri
necessarili
mean
viral
diseas
ganciclovir
consid
patient
ard
histologyor
cytologyproven
cmv
pneumonia
issu
ard
sometim
result
viral
involv
lung
subsequ
initi
viral
lunginfectioninduc
damag
viral
lung
diseas
intens
care
unit
icu
roughli
divid
two
categori
communityacquir
viral
diseas
respiratori
virus
top
list
nosocomi
viral
infect
herpesvirida
name
herp
simplex
viru
hsv
cytomegaloviru
cmv
review
address
epidemiolog
manag
outcom
virusinduc
ard
nonimmonosuppress
patient
acut
respiratori
distress
syndrom
due
respiratori
virus
communityacquir
viral
diseas
virus
held
respons
communityacquiredpneumonia
case
studi
influenza
frequent
viru
detect
virus
caus
sever
pneumonia
ard
two
differ
situat
distinguish
viral
pneumonia
ard
due
season
respiratori
virus
pandem
virus
virus
identifi
etiolog
roughli
communityacquiredpneumonia
reach
studi
studi
influenza
rhinovirus
detect
frequent
follow
respiratori
virus
like
parainfluenza
adenoviru
respiratori
syncyti
viru
coronavirus
recent
human
metapneumoviru
virus
caus
sever
pneumonia
ard
requir
mechan
ventil
mv
although
unknown
precis
frequenc
complic
probabl
low
past
year
three
differ
virus
respons
acut
respiratori
failur
ard
novel
coronaviru
caus
sever
acut
respiratori
syndrom
sar
pandem
two
new
influenza
virusesavian
influenza
influenza
unusu
pneumonia
diagnos
china
within
month
emerg
affect
patient
caus
death
countri
five
contin
respons
pathogen
new
coronaviru
sarscov
sever
acut
respiratori
syndrom
sar
affect
person
age
slight
femal
predomin
probabl
reflect
increas
likelihood
exposur
nurs
initi
symptom
includ
fever
chill
myalgia
cough
also
short
breath
andor
tachypnea
chest
xray
show
abnorm
patient
pandem
onethird
sar
patient
simpl
cours
twothird
develop
sever
complic
inde
infect
patient
requir
icu
admiss
larg
major
requir
mv
ard
manag
sar
patient
includ
prevent
humantohuman
transmiss
sever
ill
patient
specif
manag
strategi
appli
protect
mv
usual
rescu
therapi
eg
nitric
oxid
prone
posit
recruit
manoeuvr
critic
ill
patient
given
ribavirin
broadspectrum
antivir
also
receiv
broadspectrum
antibiot
includ
drug
effect
agent
caus
atyp
pneumonia
howev
treatment
demonstr
clinic
efficaci
corticosteroid
given
sever
ill
patient
effect
resolv
pneumonia
chest
film
opac
control
trial
confirm
observ
predict
resurg
sar
difficult
probabl
low
viru
longer
seem
circul
avian
influenza
viru
first
describ
caus
sever
pneumonia
often
progress
rapidli
ard
viru
continu
provok
human
diseas
cumul
case
report
world
health
organ
sinc
casefat
rate
nearli
symptom
infect
human
common
nonspecif
includ
fever
dyspnea
cough
vomit
diarrhea
headach
etc
howev
case
pneumonia
progress
rapidli
acut
respiratori
failur
ard
clinic
factor
might
associ
sever
includ
older
age
year
late
consult
lower
respiratori
tract
lesion
andor
leukopenia
patient
previous
healthi
direct
aviantohuman
transmiss
predomin
mean
human
infect
humantohuman
transmiss
probabl
limit
autopsi
patient
succumb
infect
found
diffus
alveolar
damag
hyalin
membran
format
patchi
interstiti
lymphoplasmacyt
infiltr
bronchiol
squamou
metaplasia
andor
pulmonari
congest
variou
degre
hemorrhag
nonspecif
clinic
radiolog
characterist
diseas
often
result
misdiagnosi
subsequ
confirm
case
convent
realtim
revers
transcriptasepolymeras
chain
reaction
rtpcr
detect
viral
rna
best
diagnost
method
diseas
still
endem
poultri
part
asia
africa
middl
east
clinician
must
awar
rare
fulmin
ard
etiolog
particularli
travel
pulmonari
symptom
unknown
origin
manag
patient
ard
remain
nonspecif
although
humantohuman
transmiss
frequent
isol
recommend
treatment
highdos
oseltamivir
eg
mg
twice
daili
day
recommend
oseltamivirresist
variant
compassion
use
intraven
zanamivir
treat
serious
ill
patient
show
promis
result
although
new
intraven
administ
neuraminidaseinhibitor
peramivir
demonstr
antivir
activ
yield
encourag
result
lethal
infect
mice
data
lack
human
corticosteroid
use
routin
efficaci
demonstr
also
use
might
increas
infecti
complic
rate
therapeut
modal
nonspecif
includ
mv
rescu
strategi
sever
ard
nitric
oxid
recruit
manoeuvr
highfrequ
oscil
andor
extracorpor
membran
oxygen
ecmo
organ
support
new
influenza
viru
detect
california
initi
spread
among
individu
mexico
unit
state
canada
viru
spread
global
caus
first
influenza
pandem
sinc
circul
outsid
usual
influenza
season
northern
hemispher
infect
trigger
broad
spectrum
clinic
syndrom
rang
afebril
upper
respiratori
ill
fulmin
viral
pneumonia
ill
caus
viru
acut
selflimit
children
young
adult
suscept
spare
adult
year
old
howev
sever
case
ard
describ
figur
pandem
risk
factor
sever
diseas
complic
pregnanc
chronic
cardiovascular
condit
congest
heart
failur
atherosclerot
diseas
chronic
lung
disord
eg
asthma
chronic
obstruct
pulmonari
diseas
cystic
fibrosi
morbid
obes
hemoglobinopathi
chronic
renal
diseas
cirrhosi
age
year
howev
approxim
onequart
onehalf
patient
hospit
die
known
coexist
medic
condit
main
syndrom
lead
icu
hospit
consist
diffus
viral
pneumon
associ
sever
hypoxemia
ard
sometim
shock
renal
failur
account
approxim
icu
admiss
infect
rapid
progress
common
typic
start
day
influenza
onset
intub
often
requir
within
hour
admiss
autopsi
patient
die
infect
viru
local
along
respiratori
tract
upper
respiratori
tract
alveoli
promin
histopatholog
featur
diffus
alveolar
damag
lung
patient
examin
alveolar
hemorrhag
intraalveolar
edema
perivascul
microthrombi
andor
pulmonari
embol
also
observ
alveolar
line
cell
includ
type
type
ii
pneumocyt
primari
cell
infect
notabl
bacteri
coinfect
identifi
patient
manag
patient
ard
due
infect
includ
earli
administr
highdos
oseltamivir
day
bioavail
critic
ill
f
g
u
r
e
f
g
virusinduc
acut
respiratori
distress
syndrom
epidemiolog
manag
outcom
patient
receiv
oseltamivir
nasogastr
tube
appear
similar
patient
uncompl
flu
patient
oseltamivirresist
variant
success
compassion
use
intraven
zanamivir
report
peramivir
recent
author
emerg
use
unit
state
corticosteroid
recommend
although
roughli
half
patient
receiv
corticosteroid
publish
seri
use
associ
higher
rate
nosocomi
infect
mortal
sever
flu
figur
rescu
therapi
frequent
use
critic
ill
patient
rang
prone
posit
nitric
oxid
administr
ecmo
patient
receiv
ecmo
favor
outcom
sinc
surviv
discharg
hospit
famili
includ
main
virus
respons
nosocomi
viral
infect
pertin
icu
patient
initi
phase
inflammatori
respons
antiinflammatori
respons
becom
predomin
lead
immunoparalysi
latter
phase
nosocomi
infect
reactiv
latent
virus
occur
common
latent
virus
reactiv
period
herpesvirida
particularli
hsv
cmv
hsv
detect
lower
respiratori
tract
icu
patient
depend
popul
diagnost
method
use
case
hsv
recoveri
lower
respiratori
tract
sampl
nonimmunocompromis
ventil
patient
correspond
viral
contamin
mouth
throat
patient
real
hsv
bronchopneumon
develop
evolv
ard
tuxen
et
al
show
patient
ard
virolog
histolog
evid
hsv
tracheobronch
recent
hsv
bronchopneumon
diagnos
nonimmunocompromis
patient
prolong
mv
patient
hsv
bronchopneumon
probabl
initi
viral
reactiv
throat
possibl
secondari
critic
ill
local
microtrauma
caus
endotrach
gastric
tube
oropharyng
caviti
suction
follow
contamin
colon
infect
bronchial
tree
lung
descend
infect
hsv
reactiv
throat
occur
icu
patient
studi
nonimmunocompromis
patient
ventil
least
day
hsv
reactiv
throat
diagnos
patient
asymptomat
wherea
associ
herpet
ulcer
lip
gingivostomat
mechan
lead
reactiv
probabl
multifactori
includ
immunoparalysi
microtrauma
due
intub
hormon
factor
reactiv
first
step
viral
ventilatorassoci
pneumonia
follow
tracheal
colon
lung
involv
although
hsv
reactiv
throat
occur
earli
icu
patient
hsv
bronchopneumon
gener
occur
later
mean
day
mv
clinic
symptom
hsv
bronchopneumon
nonspecif
frequent
mimic
bacteri
pneumonia
fever
hypoxemia
purul
tracheal
secret
gingivostomat
herpet
ulcer
lip
figur
even
smaller
lesion
frequent
associ
hsv
bronchopneumon
thu
orallabi
lesion
mechan
ventil
patient
especi
ard
patient
incit
search
hsv
bronchopneumon
origin
ard
cytolog
examin
cell
cornerston
hsvbronchopneumon
diagnosi
hsv
ard
inde
hsv
detect
automat
mean
viral
infect
reflect
either
contamin
mouth
andor
throat
bronchial
specimen
local
tracheobronchi
viru
excret
hsvspecif
nuclear
inclus
detect
cell
recov
bronchoscop
bronchoalveolar
lavag
bal
diagnos
parenchym
lung
involv
figur
techniqu
may
difficult
implement
daili
practic
requir
train
intensivist
pathologist
specif
skill
anoth
way
diagnos
hsv
bronchopneumon
could
virusload
assess
approach
f
g
u
r
e
f
g
herp
simplex
viru
orallabi
lesion
base
fact
higher
viru
load
higher
incid
hsv
bronchopneumon
shown
threshold
hsv
cell
sensit
ci
specif
ci
diagnos
hsv
bronchopneumon
oropharyng
tracheobronchi
hsv
carriag
associ
prolong
hospit
stay
higher
mortal
patient
hsv
bronchopneumon
requir
longer
mv
without
mortal
group
studi
author
perform
casecontrol
subanalysi
match
baselin
criteria
control
age
ae
year
simplifi
acut
physiolog
score
ii
ae
mccabe
jackson
comorbid
score
postcardiac
surgeri
reason
pursu
mv
mv
durat
least
equal
time
hsv
bronchopneumon
onset
pair
case
patient
hsv
bronchopneumon
mv
longer
stay
icu
longer
match
patient
anoth
studi
show
patient
high
viru
load
bal
fluid
genom
equivalentsml
poorer
outcom
patient
whose
viru
load
cutoff
unfortun
exact
signific
hsv
detect
lower
respiratori
tract
still
debat
mean
true
hsv
lung
diseas
morbid
andor
mortal
mere
marker
diseas
sever
acyclovir
deriv
lvalin
ester
valacyclovir
achiev
good
lung
bioavail
diffus
howev
spars
data
avail
outcom
acyclovirtr
patient
hsv
lung
involv
publish
data
either
case
report
cohort
studi
prospect
studi
luyt
et
al
evalu
nonimmunocompromis
patient
hsv
bronchopneumon
among
treat
acyclovir
receiv
antivir
mv
durat
hsvbronchopneumon
clinic
cours
mortal
rate
compar
howev
studi
random
design
test
acyclovir
set
avail
doubleblind
placebocontrol
random
studi
ard
patient
perform
tuxen
et
al
author
show
acyclovir
could
prevent
herpet
reactiv
lower
respiratori
tract
hsv
detect
tracheal
aspir
acyclovirtr
patient
vs
placebotr
subject
howev
mortal
rate
two
group
vs
respect
mv
durat
ae
vs
ae
day
respect
frequenc
recent
larg
multicent
studi
critic
ill
nonimmunocompromis
patient
found
cytomegaloviru
cmv
viremia
level
icu
stay
cmv
viremia
copiesml
howev
data
focus
cmv
reactiv
blood
recogn
long
ago
cmv
lung
diseas
studi
examin
cmv
pneumonia
nonimmunocompromis
icu
patient
frequenc
cmv
detect
lung
rang
depend
popul
test
icu
patient
screen
lung
cmv
rare
found
wherea
consid
exclus
patient
unexplain
ard
increas
frequenc
cmv
detect
blood
median
icu
stay
day
highest
viremia
detect
median
day
icu
circul
cmv
reactiv
exact
time
frequenc
test
remain
determin
nonimmunocompromis
patient
wherea
weekli
assay
suffici
immunocompromis
pcr
detect
cmv
dna
blood
realtim
pcr
quantifi
patient
cmv
lung
diseas
infect
occur
prolong
mv
roughli
mean
week
cmv
pneumonia
first
identifi
lung
parenchyma
biopsi
techniqu
cumbersom
hard
implement
daytoday
practic
date
specif
test
cmv
pneumonia
valid
lung
histolog
recent
studi
patient
consid
develop
cmv
pneumonia
follow
two
criteria
met
clinic
sign
lead
bal
f
g
u
r
e
f
g
herp
simplex
virusspecif
nuclear
inclus
cell
recov
bronchoalveolar
lavag
fluid
virusinduc
acut
respiratori
distress
syndrom
epidemiolog
manag
outcom
ard
suspect
ventilatorassoci
pneumonia
either
cmv
recoveri
lower
respiratori
tract
posit
cytopath
effect
bal
fluid
howev
strategi
might
fals
increas
cmvpneumonia
rate
inde
hsv
bronchopneumon
import
bear
mind
viru
isol
bal
fluid
necessarili
mean
viral
infect
viral
diseas
cmv
recoveri
lower
respiratori
tract
might
reactiv
without
true
lung
involv
suspect
viral
pneumonia
cytolog
examin
look
specif
viral
inclus
balcollect
cell
foundat
stone
diagnosi
moreov
cytopath
effect
depend
herpesvirida
consid
nuclear
inclus
specif
hsv
infect
figur
cytoplasm
inclus
specif
cmv
infect
figur
techniqu
probabl
less
sensit
cmv
pneumonia
hsv
bronchopneumon
recent
studi
cmv
infect
icu
patient
posit
cytopath
effect
bal
fluid
observ
one
patient
diagnos
cmv
pneumonia
virolog
techniqu
like
virusload
determin
replac
histolog
near
futur
recommend
clinician
test
bal
fluid
cmv
case
unexplain
ard
pneumonia
symptom
identifi
pathogen
bal
fluid
also
sent
patholog
depart
look
cytopath
effect
data
avail
prognosi
cmv
pneumonia
howev
cmv
reactiv
blood
seem
associ
poor
outcom
one
studi
evalu
outcom
patient
cmv
pneumonia
cmv
infect
defin
posit
antigenemia
isol
cmv
bal
fluid
posit
cytopath
effect
bal
cell
sign
andor
symptom
pulmonari
diseas
combin
cmv
detect
bal
fluid
lungtissu
sampl
although
outcom
patient
cmv
pneumonia
alon
mention
accord
univari
analysi
mortal
nonsignificantli
higher
patient
cmv
infect
without
hsv
bronchopneumon
imposs
know
whether
cmv
detect
lower
respiratori
tract
mere
marker
diseas
sever
signal
real
diseas
morbiditymort
date
random
control
trial
test
use
anticmv
drug
icu
patient
suspect
proven
cmv
pneumonia
studi
cmv
pneumonia
suspect
unexplain
ard
confirm
openlung
biopsi
patient
treat
ganciclovir
main
anticmv
agent
recov
drug
high
toxic
lack
strong
data
concern
potenti
benefit
possibl
conclud
use
icu
patient
ard
rare
complic
lung
infect
due
respiratori
virus
except
recent
pandem
influenza
virus
induc
sever
ard
specif
manag
includ
antivir
treatment
oseltamivir
influenza
virus
avoid
corticosteroid
seem
deleteri
icu
patient
ard
may
due
aggrav
hsv
bronchopneumon
cmv
pneumonia
pathogen
reactiv
respons
immunoparalysi
sever
day
icu
stay
hsv
cmv
recoveri
lower
respiratori
tract
necessarili
mean
viral
diseas
identif
lead
search
true
parenchym
involv
either
cytolog
virusload
determin
specif
manag
includ
acyclovir
patient
ard
hsv
bronchopneumon
use
ganciclovir
patient
cmv
pneumonia
discuss
patient
patient
ventilatori
manag
patient
virusinduc
ard
ard
etiolog
notabl
pandem
renew
interest
potenti
lifesav
interest
salvag
therapi
ecmo
studi
need
confirm
contribut
ard
manag
cytomegalovirusspecif
cytoplasm
inclus
cell
recov
bronchoalveolar
lavag
fluid
